On 26 August 2020,following unexpectedly strong,post-initial-lockdown resurgences of coronavirus disease 2019(COVID-19)in the late spring and summer,the medical-manufacturer giant Abbott and the US federal government announced approval,for emergency use in public health efforts to control the pandemic,of a new diagnostic testing device the size of a credit card and cost-ing only 5 USD apiece[1].